Close

Anti-IL13RA2 (XP255) h(4-1BB-CD3ζ) CAR-CIK Cells (XS-0722-ZP267)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cytokine-induced killer (CIK) cells are a heterogeneous population of polyclonal T cells that acquire phenotypic and cytotoxic properties of natural killer (NK) cells through the cultivation process, becoming so-called T-NK cells. CIK cells are capable of killing tumors in an unrestricted major histocompatibility complex (MHC) manner and can be genetically modified to express CARs. Taken together, the promising safety profile of patients in an allogeneic setting, MHC-independent cytotoxicity capability, and unique NK cell-like phenotype make CAR CIK cells a viable alternative for targeting cancer.

Our CAR CIK cells are engineeried by incorporation of second-generation CAR into PBMC-derived CIK cells using the non-viral Sleeping Beauty (SB) transposon or CAR lentivirus transduction technology. These CAR CIK cells are expected to exhibit robust antitumor activity in xenograft mouse models compared to unmodified CIK cells.

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Specifications

  • Species
  • Human
  • Host Cell Type
  • CAR-CIK Cells
  • Mycoplasma Testing
  • The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
  • Shipping
  • Dry ice
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C). Once reconstituted, the cells may be used for up to five days if properly stored at 2°C - 8°C in the buffer provided.
  • Warnings
  • Avoid multiple freeze/thaw cycles
  • Research Use Only
  • Our CAR cells are for research use only, not for diagnostic or therapeutic use.
  • Quality Control
  • Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification).
  • Sterility Testing
  • All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
  • Virological Safety Testing
  • A broad range of viruses is susceptible to affecting human cell lines. We can provide in vivo/vitro virus saftey assays by utilizing various animal systems. These viruses include: adventitious viruses, bovine viruses, human and simian viruses, porcine viruses, retrovirus and rodent viruses.

CAR Design

  • Target
  • IL13RA2
  • Target Species
  • Human
  • scFv Clone
  • XP255
  • scFv Host Spcies
  • Mouse
  • CAR Construction
  • scFv-4-1BB-CD3ζ
  • CAR Signaling Cassetes
  • 4-1BB
    4-1BB (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide costimulatory signals required for T cell activation and survival. 4-1BB is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). 4-1BB modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. 4-1BB enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the 4-1BB endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And 4-1BB results in a brightly expressed, stable receptor as the transmembrane domain. Including 4-1BB costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric 4-1BB and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
  • CAR Vector Name
  • pCDCAR1
  • CAR Vector length
  • ~8kb
  • CAR Vector Type
  • Lentiviral vector
  • CAR Generation
  • Second
  • Targeting Diseases
  • Multiple Myeloma

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-IL13RA2 (XP255) h(4-1BB-CD3ζ) CAR-CIK Cells (XS-0722-ZP267). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.